scispace - formally typeset
F

Francesco E. Pontieri

Researcher at Sapienza University of Rome

Publications -  140
Citations -  8326

Francesco E. Pontieri is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Parkinson's disease & Dopaminergic. The author has an hindex of 35, co-authored 128 publications receiving 7542 citations. Previous affiliations of Francesco E. Pontieri include National Institutes of Health & University of Cagliari.

Papers
More filters
Journal ArticleDOI

Drug addiction as a disorder of associative learning. Role of nucleus accumbens shell/extended amygdala dopamine.

TL;DR: Addiction is the expression of the excessive control over behavior acquired by drug‐related stimuli as a result of abnormal strenghtening of stimulus‐drug contingencies by nondecremental drug‐induced stimulation of dopamine transmission in the nucleus accumbens shell.
Journal ArticleDOI

The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life.

TL;DR: Overall non-motor symptom progression does not follow motor deterioration, is symptom-specific, and only development of specific domains negatively impacts quality of life, which has consequences for drug studies targeting non-Motor features.
Journal ArticleDOI

Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine.

TL;DR: It is suggested that amphetamine and cocaine increase extracellular DA in the PFCX largely through the blockade of the NA carrier, and direct evidence for this hypothesis was provided by the observation that, when theNA carrier was blocked by reverse dialysis of the P FCX with desipramine, cocaine and GBR 12909 lost their differences in the ability to increase extracllular DA.
Journal ArticleDOI

Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial

TL;DR: This study provides Class I evidence that riluzole reduces, by at least 5 points, the International Cooperative Ataxia Rating Scale (ICARS) score in patients with a wide range of disorders that cause cerebellar ataxia.